research Long-term Efficacy and Safety of Upadacitinib in the Treatment of Alopecia Areata: A Retrospective Study
Upadacitinib is effective and safe for long-term treatment of alopecia areata, especially for those with an atopic background.
Search
for
Sort by
Research
690-720 / 1000+ results
research Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects
Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
research The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
research Adult black dot tinea capitis caused by Trichophyton tonsurans complicated with herpes zoster
A woman with a scalp infection and herpes recovered fully after treatment.
research Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population
DPCP is effective for treating severe alopecia areata, but relapse is common.
research Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer
Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Hair follicles as immune targets: unraveling cellular players, cytokine crosstalk, and precision pathways for future therapy of alopecia areata
New therapies aim to improve long-term hair regrowth in alopecia areata by targeting immune responses.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
research Recurring Chemotherapy-Associated Alopecia Areata: Case Report and Literature Review
Chemotherapy may cause recurring hair loss due to an autoimmune response.
research Toxicity of the immune suppressant cyclosporin A in the rat
Cyclosporin A is highly toxic to rats, causing severe health issues and death.
research A Rare Complication of Tinea Capitis: Urticarial Id Reaction
Tinea capitis can rarely cause urticarial skin reactions in children.
research Drug-induced alopecia areata: A systematic review
Certain drugs can cause hair loss, but stopping the drug usually leads to hair regrowth.
research THE HUMAN HAIR FOLLICLE AS SENTINEL FOR DRUGS EVALUATION: DEMONSTRATION OF TETRACYCLINE ADHESION TO HAIR FOLLICLE AS PROPOSED MECHANISM IN DYSFUNCTIONAL HAIR LOSS
Tetracycline can stick to hair follicles and potentially cause hair loss.
research Prior antigen experience influences the development of alopecia areata in C3H/HeJ mice 2258436
Prior infections reduced alopecia areata development in mice.
research Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial
research 3162 Alopecia universalis after alemtuzumab in multiple sclerosis - a nine year follow up and review of literature
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
research Multiple sclerosis: Side effects of interferon beta therapy and their management
The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
research Hypertrichosis and topical corticosteroid use
Prolonged use of topical corticosteroids can cause excessive hair growth.
research SAT340 Matters Of The HAART - Ritonavir Induced CYP3A4 Inhibition of Intranasal Fluticasone Leading To Cushing’s Syndrome
HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.
research Anti-anginal and beta-adrenoceptor blocking drugs
Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.
research Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Severe and Fatal Phenobarbitone Eruptions
Phenobarbitone can cause severe and sometimes fatal skin reactions.
research Alopecia side-effect of antituberculosis drugs
Some tuberculosis drugs may cause hair loss, but hair might regrow after treatment or changing the drugs.
research Reply to “Regarding the risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases”
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.